|
US7597886B2
(en)
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
|
US6812327B1
(en)
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
US6689579B1
(en)
|
1996-10-25 |
2004-02-10 |
Human Genome Sciences, Inc. |
Polynucleotides encoding neutrokine-α
|
|
AU5705898A
(en)
*
|
1996-12-17 |
1998-07-15 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
CA2232743A1
(en)
*
|
1997-04-02 |
1998-10-02 |
Smithkline Beecham Corporation |
A tnf homologue, tl5
|
|
IL133315A0
(en)
*
|
1997-06-06 |
2001-04-30 |
Regeneron Pharma |
Ntn-2 member of tnf ligand family
|
|
JP2002517977A
(ja)
*
|
1997-06-06 |
2002-06-18 |
リジェネロン ファーマシューティカルズ，インコーポレイテッド |
Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
|
|
WO1999011791A2
(en)
*
|
1997-09-05 |
1999-03-11 |
University Of Washington |
Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
|
|
CA2303424A1
(en)
*
|
1997-09-12 |
1999-03-18 |
Jurg Tschopp |
Kay - a novel immune system protein
|
|
JP2002503444A
(ja)
*
|
1997-11-26 |
2002-02-05 |
イーライ・リリー・アンド・カンパニー |
リガンドファミリー遺伝子
|
|
US6297367B1
(en)
*
|
1997-12-30 |
2001-10-02 |
Chiron Corporation |
Polynucleotide encoding TNFL1
|
|
WO1999033980A2
(en)
*
|
1997-12-30 |
1999-07-08 |
Chiron Corporation |
Members of tnf and tnfr families
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
GB9828628D0
(en)
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
DE60043626D1
(de)
*
|
1999-01-07 |
2010-02-11 |
Zymogenetics Inc |
Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
BR0007719A
(pt)
*
|
1999-01-25 |
2001-11-13 |
Biogen Inc |
Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US6475986B1
(en)
*
|
1999-02-02 |
2002-11-05 |
Research Development Foundation |
Uses of THANK, a TNF homologue that activates apoptosis
|
|
CN100439499C
(zh)
*
|
1999-02-23 |
2008-12-03 |
人体基因组科学有限公司 |
Neutrokine-α和Neutrokine-α剪接变体
|
|
NZ513290A
(en)
*
|
1999-02-23 |
2004-05-28 |
Human Genome Sciences Inc |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
US6534061B1
(en)
|
1999-04-12 |
2003-03-18 |
Genentech, Inc. |
Tumor necrosis factor receptor homologs and nucleic acids encoding the same
|
|
US20030022233A1
(en)
|
1999-04-30 |
2003-01-30 |
Raymond G. Goodwin |
Methods of use of the taci/taci-l interaction
|
|
WO2000068378A1
(en)
*
|
1999-05-06 |
2000-11-16 |
National Jewish Medical And Research Center |
Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
|
|
CN101633692A
(zh)
|
1999-06-28 |
2010-01-27 |
杰南技术公司 |
利用二价金属离子制备Apo-2配体的方法
|
|
UA75049C2
(uk)
|
1999-08-17 |
2006-03-15 |
Байоджен Айдек Ма Інк. |
Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
|
|
UA74798C2
(uk)
|
1999-10-06 |
2006-02-15 |
Байоджен Айдек Ма Інк. |
Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
|
|
JP2003521931A
(ja)
|
2000-02-11 |
2003-07-22 |
バイオジェン インコーポレイテッド |
Ｔｎｆファミリーの異種ポリペプチド
|
|
CA2396793A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US6969519B2
(en)
|
2000-03-10 |
2005-11-29 |
Human Genome Sciences, Inc. |
Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
|
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
|
EP2206720A1
(en)
|
2000-04-12 |
2010-07-14 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20020086018A1
(en)
|
2000-05-12 |
2002-07-04 |
Theill Lars Eyde |
Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
|
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
US7220840B2
(en)
|
2000-06-16 |
2007-05-22 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator protein
|
|
PT1303293E
(pt)
|
2000-07-27 |
2009-03-11 |
Genentech Inc |
Administração sequencial de cpt-11 e polipéptido apo-2l
|
|
EP1309718A4
(en)
*
|
2000-08-15 |
2004-08-25 |
Human Genome Sciences Inc |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
WO2002016411A2
(en)
|
2000-08-18 |
2002-02-28 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
US20030012783A1
(en)
|
2001-02-20 |
2003-01-16 |
Wayne Kindsvogel |
Antibodies that bind both BCMA and TACI
|
|
ATE549354T1
(de)
|
2001-05-11 |
2012-03-15 |
Amgen Inc |
Peptide und damit zusammenhängende an tall-1 bindende moleküle
|
|
BRPI0209933B8
(pt)
|
2001-05-24 |
2021-05-25 |
Zymogenetics Inc |
proteína de fusão, e, molécula de ácido nucleico
|
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
|
WO2003066661A2
(en)
|
2001-07-03 |
2003-08-14 |
Genentech, Inc. |
Human dr4 antibodies and uses thereof
|
|
AR035119A1
(es)
|
2001-08-16 |
2004-04-14 |
Lilly Co Eli |
Anticuerpos humanos antagonistas anti-htnfsf13b
|
|
IL161051A0
(en)
|
2001-10-02 |
2004-08-31 |
Genentech Inc |
Apo-2 ligand variants and uses thereof
|
|
EP1507793A4
(en)
*
|
2001-10-17 |
2006-02-01 |
Human Genome Sciences Inc |
NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION
|
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
ES2351786T3
(es)
|
2001-11-13 |
2011-02-10 |
Genentech, Inc. |
Formulaciones con ligando apo2/trail y usos de las mismas.
|
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
|
WO2004058309A1
(en)
*
|
2002-12-23 |
2004-07-15 |
Human Genome Sciences, Inc. |
Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
|
|
WO2004094620A2
(en)
|
2003-03-28 |
2004-11-04 |
Biogen Idec Ma Inc. |
Truncated baff receptors
|
|
PL1631313T3
(pl)
|
2003-06-05 |
2015-08-31 |
Genentech Inc |
Terapia skojarzona zaburzeń z komórek B
|
|
WO2005051994A2
(en)
*
|
2003-11-21 |
2005-06-09 |
Zymogenetics, Inc. |
Ztnf11, a tumor necrosis factor
|
|
CA2554526A1
(en)
*
|
2004-01-29 |
2005-08-18 |
Genentech, Inc. |
Variants of the extracellular domain of bcma and uses thereof
|
|
JP4897676B2
(ja)
|
2004-07-02 |
2012-03-14 |
バイオ‐レイヤー ピーティーワイ リミティッド |
金属錯体の使用方法
|
|
PL1774037T3
(pl)
|
2004-08-06 |
2011-09-30 |
Genentech Inc |
Oznaczenia i sposoby wykorzystujące biomarkery
|
|
MX2007001469A
(es)
|
2004-08-06 |
2007-03-26 |
Genentech Inc |
Ensayos y metodos que utilizan biomarcadores.
|
|
EP1801231B1
(en)
|
2004-09-15 |
2011-11-30 |
Kowa Co., Ltd. |
Method of screening baff suppressor or inhibitor
|
|
CA2580271A1
(en)
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
|
NZ583905A
(en)
|
2004-10-13 |
2011-12-22 |
Univ Washington |
Use of BAFF to Treat Sepsis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006067210A1
(en)
|
2004-12-23 |
2006-06-29 |
Laboratoires Serono S.A. |
Bcma polypeptides and uses thereof
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
EP1922079A2
(en)
|
2005-08-09 |
2008-05-21 |
ZymoGenetics, Inc. |
Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
|
|
AU2006278229B2
(en)
|
2005-08-09 |
2011-10-27 |
Ares Trading S.A. |
Methods for treating B-cell malignancies using TACI-Ig fusion molecule
|
|
JP5186372B2
(ja)
|
2005-08-16 |
2013-04-17 |
ジェネンテック， インコーポレイテッド |
細胞／組織においてｇａｌｎａｃ−ｔ１４発現を試験することによるａｐｏ２ｌ／ｔｒａｉｌに対するアポトーシス感受性
|
|
EA015860B1
(ru)
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
WO2007062090A2
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
US8211649B2
(en)
|
2006-03-31 |
2012-07-03 |
Human Genome Sciences, Inc. |
Methods of diagnosing and prognosing hodgkin's lymphoma
|
|
JP2009537563A
(ja)
|
2006-05-15 |
2009-10-29 |
アレス トレーディング ソシエテ アノニム |
Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
|
|
CA2738472A1
(en)
|
2008-09-26 |
2010-04-22 |
Tocagen Inc. |
Gene therapy vectors and cytosine deaminases
|
|
JP5773879B2
(ja)
|
2008-11-25 |
2015-09-02 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
神経系の細胞の生存を促進するためのＤＲ６およびｐ７５のアンタゴニストの使用
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
US8728730B2
(en)
|
2009-09-03 |
2014-05-20 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
|
SG10201509499RA
(en)
|
2010-11-19 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Neutralizing anti-ccl20 antibodies
|
|
BR112013021725A2
(pt)
|
2011-02-28 |
2016-11-01 |
Genentech Inc |
marcadores biológicos e métodos para prever resposta aos antagonistas de células b
|
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
|
CN103421113B
(zh)
*
|
2012-05-22 |
2018-01-19 |
武汉华鑫康源生物医药有限公司 |
抗BLyS抗体
|
|
EP3623478A1
(en)
|
2012-10-25 |
2020-03-18 |
Tocagen Inc. |
Retroviral vector with mini-promoter cassette
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
DE102014018663A1
(de)
|
2014-12-13 |
2015-03-05 |
Heinz Kiefer |
Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren
|
|
AR104368A1
(es)
|
2015-04-03 |
2017-07-19 |
Lilly Co Eli |
Anticuerpos biespecíficos anti-cd20- / anti-baff
|
|
JP7748393B2
(ja)
|
2020-05-08 |
2025-10-02 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
|
|
KR20240019124A
(ko)
|
2021-05-07 |
2024-02-14 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
|
|
CN113238061B
(zh)
*
|
2021-07-09 |
2021-10-01 |
中南大学湘雅医院 |
以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
|
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
|
CN119799684B
(zh)
*
|
2024-12-27 |
2026-02-03 |
杭州微新生物科技有限公司 |
一种靶向无害梭菌的抗菌蛋白及其制备方法与应用
|